Art. -Nr.: HY-125817

BI-3406

12 Cited Publications

Kundenbewertung

Based on 12 publication(s) in Google Scholar

BI-3406 (compound I-6) is an orally active, highly potent and selective inhibitor of the interaction between KRAS and Son of Sevenless 1 (SOS1) with an IC₅₀ of 6 nM. BI-3406 potently reduces the formation of GTP-loaded KRAS, and inhibits MAPK pathway signaling. BI-3406 has anticancer activity.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

The BI-3406 was designed by Boehringer Ingelheim and could be obtained free of charge through the Boehringer Ingelheim open innovation portal opnMe.com, associated with its negative control.

Reinheit: 99.95%
CAS. Nr.: 2230836-55-0
Formel: C₂₃H₂₅F₃N₄O₃
Molecular Weight:462.46

Speicherung:

4°C, stored under nitrogen

* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)

BI-3406 Chemical Structure

CAS. Nr.: 2230836-55-0

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
Chemical Information
Publications (12)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target^[1]

KRAS-SOS1

6 nM (IC₅₀)

Alle Ras Isoform-spezifische Produkte anzeigen :

Alle p38 MAPK Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	106 nM Compound: 1; BI-3406	Antiproliferative activity against human A549 cells harboring KRAS G12S mutant assessed as inhibition of cell growth Antiproliferative activity against human A549 cells harboring KRAS G12S mutant assessed as inhibition of cell growth	[PMID: 38714262]
A549	IC₅₀	263 nM Compound: BI-3406	Antiproliferative activity against human A549 cells harboring KRAS G12S mutant assessed as inhibition of cell proliferation incubated for 7 days by CellTiterGlo-3D proliferation assay Antiproliferative activity against human A549 cells harboring KRAS G12S mutant assessed as inhibition of cell proliferation incubated for 7 days by CellTiterGlo-3D proliferation assay	[PMID: 36897932]
ASPC1	IC₅₀	64.4 nM Compound: BI-3406	Antiproliferative activity against human ASPC1 cells harboring KRAS G12D mutant assessed as inhibition of cell proliferation incubated for 7 days by CellTiterGlo-3D proliferation assay Antiproliferative activity against human ASPC1 cells harboring KRAS G12D mutant assessed as inhibition of cell proliferation incubated for 7 days by CellTiterGlo-3D proliferation assay	[PMID: 36897932]
DLD-1	IC₅₀	102 nM Compound: BI3406	Antiproliferative activity against human DLD-1 cells harboring G13D mutant assessed as inhibition of cell proliferation incubated for 7 days by celltiter-glo 3D assay Antiproliferative activity against human DLD-1 cells harboring G13D mutant assessed as inhibition of cell proliferation incubated for 7 days by celltiter-glo 3D assay	[PMID: 38206836]
DLD-1	IC₅₀	169 nM Compound: 1; BI-3406	Antiproliferative activity against human DLD-1 cells harboring KRAS G13D mutant assessed as inhibition of cell growth Antiproliferative activity against human DLD-1 cells harboring KRAS G13D mutant assessed as inhibition of cell growth	[PMID: 38714262]
K562	IC₅₀	1.422 μM Compound: BI-3406	Antiproliferative activity against human K562 cells incubated for 72 hrs by CCK8 assay Antiproliferative activity against human K562 cells incubated for 72 hrs by CCK8 assay	[PMID: 38316747]
K562	IC₅₀	37 nM Compound: 6; BI-3406	Antiproliferative activity against human K562 cells assessed as reduction in cell viability measured after 72 hrs by CellTiter-Glo luminescent cell viability assay Antiproliferative activity against human K562 cells assessed as reduction in cell viability measured after 72 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 37778239]
LoVo	IC₅₀	142 nM Compound: BI-3406	Antiproliferative activity against human LoVo cells harboring KRAS G13D mutant assessed as inhibition of cell proliferation incubated for 7 days by CellTiterGlo-3D proliferation assay Antiproliferative activity against human LoVo cells harboring KRAS G13D mutant assessed as inhibition of cell proliferation incubated for 7 days by CellTiterGlo-3D proliferation assay	[PMID: 36897932]
MIA PaCa-2	IC₅₀	24.8 nM Compound: BI-3406	Antiproliferative activity against human MIA PaCa-2 cells harboring KRAS G12C mutant assessed as inhibition of cell proliferation incubated for 7 days by CellTiterGlo-3D proliferation assay Antiproliferative activity against human MIA PaCa-2 cells harboring KRAS G12C mutant assessed as inhibition of cell proliferation incubated for 7 days by CellTiterGlo-3D proliferation assay	[PMID: 36897932]
MIA PaCa-2	IC₅₀	29 nM Compound: BI-3406	Antiproliferative activity against human MIA PaCa-2 cells incubated for 72 hrs by CCK8 assay Antiproliferative activity against human MIA PaCa-2 cells incubated for 72 hrs by CCK8 assay	[PMID: 38316747]
MIA PaCa-2	IC₅₀	30 nM Compound: 4; BI-3406	Antiproliferative activity against human MIA PaCa-2 cells harboring G12C mutant assessed as cell growth inhibition incubated for 7 days by Celltiter-Glo 3D cell viability assay Antiproliferative activity against human MIA PaCa-2 cells harboring G12C mutant assessed as cell growth inhibition incubated for 7 days by Celltiter-Glo 3D cell viability assay	[PMID: 36793426]
NCI-H358	IC₅₀	16.5 nM Compound: BI-3406	Antiproliferative activity against human NCI-H358 cells harboring KRAS G12C mutant assessed as inhibition of cell proliferation incubated for 7 days by CellTiterGlo-3D proliferation assay Antiproliferative activity against human NCI-H358 cells harboring KRAS G12C mutant assessed as inhibition of cell proliferation incubated for 7 days by CellTiterGlo-3D proliferation assay	[PMID: 36897932]
NCI-H358	IC₅₀	24 nM Compound: BI3406	Antiproliferative activity against human NCI-H358 cells assessed as reduction in cell viability Antiproliferative activity against human NCI-H358 cells assessed as reduction in cell viability	[PMID: 38206836]
NCI-H358	IC₅₀	26 nM Compound: BI3406	Antiproliferative activity against human NCI-H358 cells assessed as inhibition of cell proliferation incubated for 7 days by celltiter-glo 3D assay Antiproliferative activity against human NCI-H358 cells assessed as inhibition of cell proliferation incubated for 7 days by celltiter-glo 3D assay	[PMID: 38206836]
NCI-H358	IC₅₀	26 nM Compound: BI3406	Antiproliferative activity against human NCI-H358 cells harboring G12C mutant assessed as inhibition of cell proliferation incubated for 7 days by celltiter-glo 3D assay Antiproliferative activity against human NCI-H358 cells harboring G12C mutant assessed as inhibition of cell proliferation incubated for 7 days by celltiter-glo 3D assay	[PMID: 38206836]
NCI-H358	IC₅₀	90 nM Compound: 2; BI-3406	Antiproliferative activity against human NCI-H358 cells harboring KRAS G12C mutant assessed as inhibition of cell proliferation incubated for 5 days by celltiter-glo 3D assay Antiproliferative activity against human NCI-H358 cells harboring KRAS G12C mutant assessed as inhibition of cell proliferation incubated for 5 days by celltiter-glo 3D assay	[PMID: 38894918]
NCI-H441	IC₅₀	68 nM Compound: BI3406	Antiproliferative activity against human NCI-H441 cells harboring G12V mutant assessed as inhibition of cell proliferation incubated for 7 days by celltiter-glo 3D assay Antiproliferative activity against human NCI-H441 cells harboring G12V mutant assessed as inhibition of cell proliferation incubated for 7 days by celltiter-glo 3D assay	[PMID: 38206836]
PANC-1	IC₅₀	17.8 nM Compound: BI-3406	Antiproliferative activity against human PANC-1 cells harboring KRAS G12D mutant assessed as inhibition of cell proliferation incubated for 7 days by CellTiterGlo-3D proliferation assay Antiproliferative activity against human PANC-1 cells harboring KRAS G12D mutant assessed as inhibition of cell proliferation incubated for 7 days by CellTiterGlo-3D proliferation assay	[PMID: 36897932]
PC-3	IC₅₀	1.37 μM Compound: BI-3406	Synergistic antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth incubated for 72 hrs in presence of gefitinib by MTT assay Synergistic antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth incubated for 72 hrs in presence of gefitinib by MTT assay	[PMID: 38630077]
PC-3	IC₅₀	8.75 μM Compound: BI-3406	Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 38630077]
SW-620	IC₅₀	30.1 nM Compound: BI-3406	Antiproliferative activity against human SW620 cells harboring KRAS G12V mutant assessed as inhibition of cell proliferation incubated for 7 days by CellTiterGlo-3D proliferation assay Antiproliferative activity against human SW620 cells harboring KRAS G12V mutant assessed as inhibition of cell proliferation incubated for 7 days by CellTiterGlo-3D proliferation assay	[PMID: 36897932]
SW-620	IC₅₀	50.5 nM Compound: 1; BI-3406	Antiproliferative activity against human SW620 cells harboring KRAS G12V mutant assessed as inhibition of cell growth Antiproliferative activity against human SW620 cells harboring KRAS G12V mutant assessed as inhibition of cell growth	[PMID: 38714262]

In Vitro

BI-3406 is an inhibitor of the interaction between KRAS and its Guanine Nucleotide Exchange Factor (GEF) SOS1. BI-3406 does not block the interaction of KRAS with SOS2 but elicits activity on a broad panel of KRAS oncogenic variants, including all major G12 and G13 oncoproteins. Down-modulation of this signaling cascade by BI-3406 in KRAS G12 or G13 mutant cells effectively limits cell proliferation^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS. Nr. 2230836-55-0
Appearance Solid
Molecular Weight 462.46
Formel C₂₃H₂₅F₃N₄O₃
Color White to off-white
SMILES

CC1=NC(N[C@@H](C2=CC(C(F)(F)F)=CC(N)=C2)C)=C3C=C(O[C@@H]4COCC4)C(OC)=CC3=N1
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

4°C, stored under nitrogen

* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)

Publications (12)

All WBCell Migration/Invasion AssayCell Imaging/StainingCell Proliferation/Viability AssayIn Vivo Efficacy Study

Sort by:

Journal Impact Factor

Cancer Cell

A pan-KRAS inhibitor and its derived degrader elicit multifaceted anti-tumor efficacy in KRAS-driven cancers. [Abstract]

2025 Jul 25:S1535-6108(25)00310-1. PMID: 40780213
Cancer Cell

Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRAS G12D-mutant cancer. [Abstract]

2024 Jul 8;42(7):1286-1300.e8. PMID: 38942026
Nat Cancer

Scribble mis-localization induces adaptive resistance to KRAS G12C inhibitors through feedback activation of MAPK signaling mediated by YAP-induced MRAS. [Abstract]

2023 Jun;4(6):829-843. PMID: 37277529
Cancer Res

Targeted Degradation of SOS1 Exhibits Potent Anticancer Activity and Overcomes Resistance in KRAS-Mutant Tumors and BCR-ABL-Positive Leukemia. [Abstract]

2025 Jan 2;85(1):101-117. PMID: 39437162

BI-3406 purchased from MedChemExpress. Usage Cited in: Cancer Res. 2025 Jan 2;85(1):101-117. [Abstract]

Western blot analysis of SOS1, pERK, GSPT1, and IKZF1/3 in NCI-H358 cells treated with SIAIS562055, SIAIS562092, or BI-3406 (10, 100, 1000 nM) for 24 hours.

BI-3406 purchased from MedChemExpress. Usage Cited in: Cancer Res. 2025 Jan 2;85(1):101-117. [Abstract]

Antiproliferative effects of SIAIS562055 and BI-3406 for 120 hours on KRAS-WT (293T, BxPC-3) and KRAS-mutant (NCI-H358, GP2d, HPAF-II, and SW620) cells.

BI-3406 purchased from MedChemExpress. Usage Cited in: Cancer Res. 2025 Jan 2;85(1):101-117. [Abstract]

MIA PaCa-2–xenografted mice received vehicle, SIAIS562055 (20 or 40 mg/kg/day), or BI-3406 (50 mg/kg, twice a day), then relative tumor weights were determined at indicated times.
Cell Commun Signal

Sos1 ablation alters focal adhesion dynamics and increases Mmp2/9-dependent gelatinase activity in primary mouse embryonic fibroblasts. [Abstract]

2025 Mar 3;23(1):116. PMID: 40033301

BI-3406 purchased from MedChemExpress. Usage Cited in: Cell Commun Signal. 2025 Mar 3;23(1):116. [Abstract]

Vehicle- (DMSO) or BI-3406-treated (1 µM) confluent WT primary MEFs were scratched with a micropipette tip and closure of the wounded area was recorded for 24 h by phase-contrast photomicroscopy.
Clin Cancer Res

Cell Type-specific Adaptive Signaling Responses to KRASG12C Inhibition. [Abstract]

2021 May 1;27(9):2533-2548. PMID: 33619172
Acta Pharmacol Sin

143D, a novel selective KRASG12C inhibitor exhibits potent antitumor activity in preclinical models. [Abstract]

2023 Jul;44(7):1475-1486. PMID: 36725884

BI-3406 purchased from MedChemExpress. Usage Cited in: Acta Pharmacol Sin. 2023 Jul;44(7):1475-1486. [Abstract]

MIA PaCa-2 or NCI-H1373 cells were treated with 143D or a combination of drugs and stained with crystal violet for identifying monoclonal cell populations. 143D (10 nM), BI3406 (10 μM), trametinib (5 nM), SCH772984 (200 nM), Afatinib (10 nM).
Cell Rep

Kinetics of RTK activation determine ERK reactivation and resistance to dual BRAF/MEK inhibition in melanoma. [Abstract]

2023 May 29;42(6):112570. PMID: 37252843
RSC Med Chem

Discovery of novel SOS1 inhibitors using machine learning. [Abstract]

2024 Mar 15;15(4):1392-1403. PMID: 38665844
iScience

Serum SOS1 as a prognostic biomarker and therapeutic target for progressive liver disease. [Abstract]

2026 Jun 17;29(7):116430. PMID: 42369045
bioRxiv

Adaptive Plasticity Tumor Cells Modulate MAPK-Targeting Therapy Response in Colorectal Cancer. [Abstract]

2025 Jan 24:2025.01.22.634215. PMID: 39896605
bioRxiv

2023 Oct 6.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (216.23 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Ethanol : 100 mg/mL (216.23 mM; Need ultrasonic)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.1623 mL

10.8117 mL

21.6235 mL

5 mM

0.4325 mL

2.1623 mL

4.3247 mL

10 mM

0.2162 mL

1.0812 mL

2.1623 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (5.41 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: 2.5 mg/mL (5.41 mM); Clear solution; Need ultrasonic

This protocol yields a clear solution of 2.5 mg/mL.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (5.41 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Protocol 4

Add each solvent one by one: 10% EtOH 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (5.41 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 5

Add each solvent one by one: 10% EtOH 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (5.41 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 6

Add each solvent one by one: 10% EtOH 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (5.41 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (278 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Michael Gmachl, et al. Novel benzylamino substituted quinazolines and derivatives as sos1 inhibitors. WO2018115380A1.

[2]. Marco H Hofmann, et al. Abstract PL06-01: Discovery of BI-3406: A potent and selective SOS1::KRAS inhibitor opens a new approach for treating KRAS-driven tumors. December 2019.

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO / Ethanol	1 mM	2.1623 mL	10.8117 mL	21.6235 mL	54.0587 mL
	5 mM	0.4325 mL	2.1623 mL	4.3247 mL	10.8117 mL
	10 mM	0.2162 mL	1.0812 mL	2.1623 mL	5.4059 mL
	15 mM	0.1442 mL	0.7208 mL	1.4416 mL	3.6039 mL
	20 mM	0.1081 mL	0.5406 mL	1.0812 mL	2.7029 mL
	25 mM	0.0865 mL	0.4325 mL	0.8649 mL	2.1623 mL
	30 mM	0.0721 mL	0.3604 mL	0.7208 mL	1.8020 mL
	40 mM	0.0541 mL	0.2703 mL	0.5406 mL	1.3515 mL
	50 mM	0.0432 mL	0.2162 mL	0.4325 mL	1.0812 mL
	60 mM	0.0360 mL	0.1802 mL	0.3604 mL	0.9010 mL
	80 mM	0.0270 mL	0.1351 mL	0.2703 mL	0.6757 mL
	100 mM	0.0216 mL	0.1081 mL	0.2162 mL	0.5406 mL

Keywords

BI-3406

12 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

BI-3406

GPCR/G Protein Compound Library

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

MAPK Compound Library

Anti-Cancer Compound Library

Reprogramming Compound Library

Oxygen Sensing Compound Library

Ferroptosis Compound Library

Pyroptosis Compound Library

Orally Active Compound Library

Glutamine Metabolism Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Neurodegenerative Disease-related Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Antidepressant Compound Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Heterocyclic Compound Library

Pain-Related Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Highly Selective Inhibitors Library

Serine/Threonine Kinase Inhibitor Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Protein Kinase Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Anti-Rheumatic Arthritis Compound Library

Posttranslational Modification Library

Lactylation Compound Library

KRAS Targeted Compound Library

Publications Citing Use of MedChemExpress (MCE) BI-3406

Alle Ras Isoform-spezifische Produkte anzeigen

Alle p38 MAPK Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (12)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

BI-3406 Related Classifications

HY-125817 Related Classifications